Skip to content

Validation of an Allergic Rhinitis Control Test in Children

Validation of an Allergic Rhinitis Control Test in Children

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03075917
Acronym
ARCTEnfants
Enrollment
137
Registered
2017-03-09
Start date
2017-05-04
Completion date
2026-07-18
Last updated
2026-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Rhinitis

Keywords

Allergic rhinitis

Brief summary

Allergic rhinitis is a common condition that affects adults as well as children and adolescents, often with impaired quality of life. Patients often report a poor level of satisfaction with the effectiveness of their treatment and are always looking for more drug combinations to improve their symptom. Several tools exist for assessing control of allergic rhinitis, but none has been validated in teenagers or in children. A study conducted in 2008, resulted in the validation of a self-administered control test of allergic rhinitis (ARCT) in patients from 12 years of age. We propose to adapt ARCT adult to pediatric population from 5 to 11 years old.

Interventions

self questionnaire for allergic rhinitis control

Sponsors

University Hospital, Montpellier
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
5 Years to 11 Years
Healthy volunteers
No

Inclusion criteria

* Patients aged 5 to 11 years old, consulting a practitioner for an allergic rhinitis * Parents formulated their study participation agreement by signing the consent form.

Exclusion criteria

* Patients that are already treated for the actual episode of allergic rhinitis and are satisfied of the treatment.

Design outcomes

Primary

MeasureTime frameDescription
Score of the allergic rhinitis control self questionnaire15 daysScore of the allergic rhinitis control self questionnaire in teenagers from 5 to 11 years old.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 28, 2026